Novo Nordisk Partners With Anthropic on Drug Research

Sep 17, 2026
Novo Nordisk will test Claude models and Claude Science across research and development workflows, while expanding its use of AI for software development.
Novo Nordisk Partners With Anthropic on Drug Research

Novo Nordisk is partnering with Anthropic to use Claude models in drug discovery and development, according to Reuters. The drugmaker will initially test the models and Claude Science in research and development workflows.

Claude Science is Anthropic's workbench for computational research, which connects its models with scientific tools and databases. Novo Nordisk and Anthropic will identify scientific problems where the technology can support research into human biology and drug mechanisms.

Novo Nordisk will also use Anthropic's models for software development. The company already uses Claude to automate trial report generation, reducing the time needed to create patient documentation from months to minutes.

We hope you enjoyed this article

Free newsletter

Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.